UK markets open in 7 hours 25 minutes
  • NIKKEI 225

    26,609.31
    +439.01 (+1.68%)
     
  • HANG SENG

    23,807.00
    -482.90 (-1.99%)
     
  • CRUDE OIL

    87.27
    +0.66 (+0.76%)
     
  • GOLD FUTURES

    1,794.90
    +1.80 (+0.10%)
     
  • DOW

    34,160.78
    -7.31 (-0.02%)
     
  • BTC-GBP

    27,764.79
    +0.22 (+0.00%)
     
  • CMC Crypto 200

    840.58
    +21.07 (+2.57%)
     
  • ^IXIC

    13,352.78
    -189.34 (-1.40%)
     
  • ^FTAS

    4,230.83
    +38.13 (+0.91%)
     

Global COVID-19 Testing Market to Shrink to US$10.4 Billion by the Year 2026

·26-min read

Abstract: Global COVID-19 Testing Market to Shrink to US$10. 4 Billion by the Year 2026 . COVID-19 testing has emerged as a large market in a span of few months owing to the large-scale testing across the world.

New York, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global COVID-19 Testing Industry" - https://www.reportlinker.com/p06219575/?utm_source=GNW
However, with vaccines being launched across the world, the COVID-19 testing market is expected to slowdown in 2021, and decline rapidly in the near future as the global population starts getting vaccinated. The major testing types include RT-PCR tests, rapid antigen tests, and rapid antibody tests. Growth in the global is primarily being driven by rising incidence of COVID-19 infection and the pressing need for effective and fast testing. Announced as pandemic by the WHO, the rapid spread of the virus across countries has prompted governments to rely on massive testing, which created strong demand for COVID-19 test kits. The market for these tests is further bolstered by unavailability of an effective treatment hitherto, driving people to consider diagnostic testing as a solution to curtail the pandemic. In addition, the requirement of effective detection kits for vulnerable population, including aging people and individuals with the compromised immune system, is propelling the market. On the other hand, short supply of test kits and other components, such as RT-PCR instruments, virus control samples, and swabs, are expected to limit the market growth.

Amid the COVID-19 crisis, the global market for COVID-19 Testing estimated at US$19.3 Billion in the year 2020, is projected to decline to revised size of US$10.4 Billion by 2026, declining at a CAGR of -11.8% over the analysis period. RT-PCR Assay Kits, one of the segments analyzed in the report, is projected to record a -12.4% CAGR and shrink to US$5.5 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Immunoassay Test Strips/Cassettes segment is readjusted to a revised -10.3% CAGR for the next 7-year period. RT-PCR is the most popular diagnostic technique in the market as it is reliable, sensitive and relatively quick, offering results within 3-4 hours. It is designed to detect the presence of viral RNA in patient samples by capturing as well as amplifying specific segments of the generic material of the virus, mainly the Spike protein, envelop or N protein. The immunoassay segment is growing rapidly, due to rising acceptance of rapid immunoassay tests. The market is likely to receive a notable contribution from the point-of-care (POC) segment. These tests are easy to access and eliminate the requirement of skilled professionals.

The U.S. Market is Estimated at $5.2 Billion in 2021, While China is Forecast to Dwindle to $246.2 Million by 2026

The COVID-19 Testing market in the U.S. is estimated at US$5.2 Billion in the year 2021. China, the world`s second largest economy, is forecast to shrink to US$246.2 Million by the year 2026 trailing a negative CAGR of -30.1% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to record negative CAGR of -10.7% and -9.8% respectively over the analysis period. Within Europe, Germany is forecast to decline at approximately -9.4% CAGR. The US is a key market and growth is driven by increasing cases of DELTA variant cases, technological advances, rising healthcare spending and presence of leading providers of COVID-19 testing kits. The US has emerged as the worst-hit nation globally, holding the highest number of confirmed cases of COVID-19. The crisis has prompted the US government to allocate huge funding to medical research units for expediting the development of new diagnostic tests and pushing up the testing capacity. Growth in the European market is attributable to continuous spread of the virus across several countries, which is poised to create strong demand for kits.

Nasopharyngeal Swab Segment to Contract to $4.1 Billion by 2026

Nasopharyngeal swabs are the preferred specimen option, with clinicians considering oropharyngeal swabs in case of unavailability of nasal swabs. The use of nasopharyngeal along with oropharyngeal swabs for testing maximizes test sensitivity while limiting resource usage. In the global Nasopharyngeal Swab (Specimen Type) segment, USA, Canada, Japan, China and Europe accounting for a combined market size of US$5.9 Billion in the year 2020 will shrink to US$2.2 Billion by the close of the analysis period. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$752.7 Million by the year 2026.


Select Competitors (Total 547 Featured)

  • 3D Biomedicine Science & Technology Co., Limited

  • Abbott Laboratories

  • Advaite, Inc.

  • AlphaBiolabs Ltd

  • BGI Genomics Co. Ltd.

  • BioFire Diagnostics LLC

  • BioMedomics Inc

  • Bioscience (Tianjin) Diagnostic Technology Co., LTD

  • Cellex

  • Cepheid Inc.

  • Chembio Diagnostic Systems, Inc.

  • Co-Diagnostics Inc.

  • Dynamiker Biotechnology (Tianjin) Co., Ltd.

  • GenMark Diagnostics, Inc.

  • Hologic, Inc

  • Innovita Biological Technology Co., Ltd

  • Mayo Clinic Laboratories

  • Mylab Discovery Solutions Pvt. Ltd.

  • Ortho Clinical Diagnostics

  • Primerdesign Ltd

  • QIAGEN N.V.

  • Quidel Corporation

  • Randox Laboratories Ltd.

  • F. Hoffmann-La Roche AG

  • Safecare Biotech(Hangzhou) Co., Ltd.

  • SD Biosensor

  • Seegene Inc.

  • Shenzhen Bioeasy Biotechnology Co., Ltd.

  • Siemens Healthineers AG

  • Thermo Fisher Scientific

  • Zhejiang Orient Gene Biotech Co., LTD




Read the full report: https://www.reportlinker.com/p06219575/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Types of COVID-19 Testing
Different Types of Coronavirus Tests
Performance Analysis of COVID-19 Tests
Rapid Tests Help in Controlling the Virus
How Will COVID-19 Testing Change in 2021
Massive Testing to Become a Way of Life
COVID-19 to Drive Hospital and Diagnostic Lab Revenues in 2021
Global Market Prospects and Outlook
COVID-19 Testing Witnesses Staggering Growth Due to Rising
Incidence of Corona Virus
EXHIBIT 1: Total Number of COVID-19 Tests Conducted in the Most
Impacted Countries: As of September 1st, 2021
EXHIBIT 2: Total Number of COVID-19 Tests Worldwide in Select
Countries: As of September 1st, 2021
Molecular Tests (RT-PCR) Occupy a Predominant Share of the
COVID-19 Testing Market
Select Approved COVID-19 Molecular Assay Tests
Immunoassays to Witness Fastest Growth
Increasing Demand for Antibody Tests
How Antibody (Serology) Tests Were Approved and Developed
Select COVID-19 Immunoassay Kits
List of US FDA Approved Antigen Tests
Nasopharyngeal/Oropharyngeal Swabs Remain Primary Sample Type
Diagnostic Laboratories Constitute the Largest End-use Segment
US and Europe Dominate, Asia-Pacific to Witness Fastest Growth
RECENT MARKET ACTIVITY
Recent Launches

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS AND ISSUES
Rising Incidence of Coronavirus Cases Drive the Need for Testing
EXHIBIT 3: COVID-19 Most Impacted 18 Countries Worldwide: As on
September 1st, 2021
Pandemic Gives Rise to Innovative Partnership Models
Broader Adoption of Reverse-Transcription Polymerase Chain
Reaction-based Diagnostics
Increasing Point-of-Care Molecular Testing
Accelerated Development and Faster Adoption of New Technologies
Expansion of Manufacturing Capacity in Asia and Shift of Supply
Positioning for the Future
Some Innovative Testing Methods for COVID-19:
CRISPR
Bioluminescence Testing
Lab-on-chip Testing
LAMpore Kits
Covid-19 NudgeBox Test by DNANudge
High Risk of Infection in Geriatric Population Drives COVID-19
Testing Market
EXHIBIT 4: Expanding Elderly Population Worldwide: Breakdown of
Number of People Aged 65+ Years in Million by Geographic
Region for the Years 2019 and 2030
Rapid Test Kits Market for COVID-19 to Exhibit Exponential Growth
Select Approved COVID-19 Rapid Tests
Point-of-Care Tests Witness Rapid Growth
High-Speed NanoPCR Technology Developed for Point-of-Care
Diagnosis of COVID-19
Mass Community Testing Holds the Key for Effective COVID-19
Management
The Need for Rapid Mass Testing Pushes for Production of Novel
Testing Platforms
CRISPR Emerges as Cutting-Edge Biotechnology in COVID-19
Diagnostic Market
Innovations and Approvals
Portable PoC Test with a Smartphone Reader
Saliva Test
FDA Approves First Molecular Test for Asymptomatic Patients
New Molecular Test N1-STOP-LAMP
LumiraDx SARS-CoV-2 Antigen Test
Integration of Sophisticated Technology to Drive Market Growth
Isothermal Amplification: An Effective Alternative to RT-PCR
for COVID-19 Testing
In-home Testing for Covid-19
FDA Authorizes Home Collection Option for LabCorp?s COVID-19
Diagnostic Test
A Rapid Genomics Strategy to Trace Coronavirus
The pioneering of Rapid Genomics
Digital Healthcare Gains Spotlight Amid COVID-19 Pandemic
Digital Technologies Gaining Adoption Amid COVID-19
List of COVID-19 Contact Tracing Apps
Amazon Offers FDA-Approved COVID-19 Test
Alliance of BMGF and Life Science Companies Pledge to Improve
Access
Ensuring the Perfect Mix of COVID-19 Testing
Testing Rate & Average Turnaround Time to Results as Key Metrics
Growing Significance of Pooled Testing
Participation of Public & Private Sector
Avoiding Supply Mismatch
New Test Detects SARS-CoV-2 in Less Than Five Minutes
New COVID-19 Test Provides Faster Results and Eliminates False
Negatives
New Rapid Lateral Flow Immunoassay Developed
University of California Develops Rapid, Accurate Testing for
SARS-CoV-2 Antibodies
Abbott Plans Shipment of Tens of Millions of At-Home
Coronavirus Tests Costing $25 in Early 2021
Quidel Gains FDA Approval for Sofia 2 Antigen Test
Improving Medicine with Innovation and Technology and
Massachusetts Institute of Technology Develop COVID-19 Testing
Impact Calculator (U.S.)
Nanomix Offers eLab COVID-19 Rapid Antigen Test
Abbott Receives FDA Approval for BinaxNow
Roche Introduces Elecsys® SARS-CoV-2 Antigen test
DnaNudge Offers CovidNudge Test
Open-Source Toolkit Helps Developing Countries Meet Demand for
COVID-19 Diagnostics
3M Joins Hands with MIT?s Sikes Lab to Create Rapid &
Affordable COVID-19 Test
ZTA Biotech Announces "Breakthrough" Development with Antibody
Test
Molecular Diagnostics Firm QuantuMDx Group Set to Scale up
Production of Rapid PCR COVID-19 Device
Mologic Granted CE Mark for Rapid Antigen Test
FDA Approves Abbott?s COVID-19 Antigen Test
AptameXTM

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for COVID-19 Testing
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 2: World 7-Year Perspective for COVID-19 Testing by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2021 & 2027

Table 3: World Current & Future Analysis for RT-PCR Assay Kits
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 4: World 7-Year Perspective for RT-PCR Assay Kits by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2021 & 2027

Table 5: World Current & Future Analysis for Immunoassay Test
Strips/Cassettes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Revenues in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 6: World 7-Year Perspective for Immunoassay Test
Strips/Cassettes by Geographic Region - Percentage Breakdown of
Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2021 & 2027

Table 7: World Current & Future Analysis for Nasopharyngeal
Swab by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 8: World 7-Year Perspective for Nasopharyngeal Swab by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2021 & 2027

Table 9: World Current & Future Analysis for Oropharyngeal Swab
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 10: World 7-Year Perspective for Oropharyngeal Swab by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2021 & 2027

Table 11: World Current & Future Analysis for Nasal Swab by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 12: World 7-Year Perspective for Nasal Swab by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2021 & 2027

Table 13: World Current & Future Analysis for Other Specimen
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 14: World 7-Year Perspective for Other Specimen Types by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2021 & 2027

Table 15: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 16: World 7-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2021 & 2027

Table 17: World Current & Future Analysis for Diagnostic
Centers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Revenues in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 18: World 7-Year Perspective for Diagnostic Centers by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2021 & 2027

Table 19: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 20: World 7-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Market Overview
US Emerges as a Major Market for COVID-19 Tests
New Delta Variant Cases Cause Concern
Covid-19 Test Supply Chain Issues in the US
Challenges Associated with COVID-19 Testing
Impact of Surveillance Testing on COVID-19 Test Supply Chain
CDC Funding for Covid-19 Vaccination & Testing-Related Activities
Escalating Cases of COVID-19 Lead to Spurt in Diagnostic Test
Innovations
Uptake of At-Home Tests Remains Modest
FDA Approves 2 Rapid, At-Home Coronavirus Tests
Select Point Of Care Home Tests in the US
Pharmacies Now Offering Over-The-Counter Same-day COVID Tests
HHS Introduces Pilot Program for Cartridge-based Covid-19
Molecular Test Kits
Oura Develops New Smart Ring to Detect Covid-19 Symptoms at
Early Stage (Finland)
Issues with Existing Testing Options
Issues with At-Home and Point-of-Care Rapid Tests
Disparate Costs Continue to Plague US Covid-19 Testing
With Spike in COVID-19 Cases Roiling Testing Efforts, NIH Eyes
on Rapid Tests to Push Capacity
Promising Technologies under RADx Program
Rapid COVID Tests: Important Tool for Recovery
California University Installs Vending Machines to Dispense
COVID-19 Testing Kits to Students
FDA Assumes Lukewarm Stance to Home Tests despite COVID-19
Testing Lag in US
CMS Prioritizes Covid-19 Testing: Announces New Reimbursement
Rules
CMS Decreases Price for High-Throughput Technology-Based Covid -
19 Testing
Ageing Demographics: A Major Driving Factor
EXHIBIT 5: US Elderly Population: Expected Growth Rates Over
the Years 2005-2025
NIH Funding
Select US FDA Approved COVID-19 Tests (As of August 31, 2021)
Market Analytics
Table 21: USA Current & Future Analysis for COVID-19 Testing by
Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 22: USA 7-Year Perspective for COVID-19 Testing by
Product - Percentage Breakdown of Value Revenues for RT-PCR
Assay Kits and Immunoassay Test Strips/Cassettes for the Years
2021 & 2027

Table 23: USA Current & Future Analysis for COVID-19 Testing by
Specimen Type - Nasopharyngeal Swab, Oropharyngeal Swab, Nasal
Swab and Other Specimen Types - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 24: USA 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027

Table 25: USA Current & Future Analysis for COVID-19 Testing by
End-Use - Hospitals, Diagnostic Centers and Other End-Uses -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 26: USA 7-Year Perspective for COVID-19 Testing by
End-Use - Percentage Breakdown of Value Revenues for Hospitals,
Diagnostic Centers and Other End-Uses for the Years 2021 & 2027

CANADA
Market Overview
New Cheaper and Faster COVID-19 Rapid Test Kit Obtains Approval
Canada Approves First Antigen-Based Rapid COVID-19 Test
Government of Ontario Introduces Covid-19 Screening Tests at
Toronto Pearson International Airport
New Federal Rule in Canada for Air Passengers? COVID-19 Tests
Market Analytics
Table 27: Canada Current & Future Analysis for COVID-19 Testing
by Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 28: Canada 7-Year Perspective for COVID-19 Testing by
Product - Percentage Breakdown of Value Revenues for RT-PCR
Assay Kits and Immunoassay Test Strips/Cassettes for the Years
2021 & 2027

Table 29: Canada Current & Future Analysis for COVID-19 Testing
by Specimen Type - Nasopharyngeal Swab, Oropharyngeal Swab,
Nasal Swab and Other Specimen Types - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 30: Canada 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027

Table 31: Canada Current & Future Analysis for COVID-19 Testing
by End-Use - Hospitals, Diagnostic Centers and Other End-Uses -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 32: Canada 7-Year Perspective for COVID-19 Testing by
End-Use - Percentage Breakdown of Value Revenues for Hospitals,
Diagnostic Centers and Other End-Uses for the Years 2021 & 2027

JAPAN
Market Overview
Japan Moves to Low-Cost PCR Testing
Rapid Testing Still Costs a Bomb
Medical Clinics Edge
Market Analytics
Table 33: Japan Current & Future Analysis for COVID-19 Testing
by Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 34: Japan 7-Year Perspective for COVID-19 Testing by
Product - Percentage Breakdown of Value Revenues for RT-PCR
Assay Kits and Immunoassay Test Strips/Cassettes for the Years
2021 & 2027

Table 35: Japan Current & Future Analysis for COVID-19 Testing
by Specimen Type - Nasopharyngeal Swab, Oropharyngeal Swab,
Nasal Swab and Other Specimen Types - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 36: Japan 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027

Table 37: Japan Current & Future Analysis for COVID-19 Testing
by End-Use - Hospitals, Diagnostic Centers and Other End-Uses -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 38: Japan 7-Year Perspective for COVID-19 Testing by
End-Use - Percentage Breakdown of Value Revenues for Hospitals,
Diagnostic Centers and Other End-Uses for the Years 2021 & 2027

CHINA
China?s Qingdao Embarks on Ambitious Mission to Test Entire
Population of City for COVID-19 in Five Days
Market Analytics
Table 39: China Current & Future Analysis for COVID-19 Testing
by Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 40: China 7-Year Perspective for COVID-19 Testing by
Product - Percentage Breakdown of Value Revenues for RT-PCR
Assay Kits and Immunoassay Test Strips/Cassettes for the Years
2021 & 2027

Table 41: China Current & Future Analysis for COVID-19 Testing
by Specimen Type - Nasopharyngeal Swab, Oropharyngeal Swab,
Nasal Swab and Other Specimen Types - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 42: China 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027

Table 43: China Current & Future Analysis for COVID-19 Testing
by End-Use - Hospitals, Diagnostic Centers and Other End-Uses -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 44: China 7-Year Perspective for COVID-19 Testing by
End-Use - Percentage Breakdown of Value Revenues for Hospitals,
Diagnostic Centers and Other End-Uses for the Years 2021 & 2027

EUROPE
Market Overview
COVID-19 Testing Drives Revenue Growth
Aging Population: A Prime Growth Driver
SELECT CE-IVD APPROVED MOLECULAR ASSAYS FOR COVID-19
Market Analytics
Table 45: Europe Current & Future Analysis for COVID-19 Testing
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Revenues in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 46: Europe 7-Year Perspective for COVID-19 Testing by
Geographic Region - Percentage Breakdown of Value Revenues for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2021 & 2027

Table 47: Europe Current & Future Analysis for COVID-19 Testing
by Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 48: Europe 7-Year Perspective for COVID-19 Testing by
Product - Percentage Breakdown of Value Revenues for RT-PCR
Assay Kits and Immunoassay Test Strips/Cassettes for the Years
2021 & 2027

Table 49: Europe Current & Future Analysis for COVID-19 Testing
by Specimen Type - Nasopharyngeal Swab, Oropharyngeal Swab,
Nasal Swab and Other Specimen Types - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 50: Europe 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027

Table 51: Europe Current & Future Analysis for COVID-19 Testing
by End-Use - Hospitals, Diagnostic Centers and Other End-Uses -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 52: Europe 7-Year Perspective for COVID-19 Testing by
End-Use - Percentage Breakdown of Value Revenues for Hospitals,
Diagnostic Centers and Other End-Uses for the Years 2021 & 2027

FRANCE
Table 53: France Current & Future Analysis for COVID-19 Testing
by Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 54: France 7-Year Perspective for COVID-19 Testing by
Product - Percentage Breakdown of Value Revenues for RT-PCR
Assay Kits and Immunoassay Test Strips/Cassettes for the Years
2021 & 2027

Table 55: France Current & Future Analysis for COVID-19 Testing
by Specimen Type - Nasopharyngeal Swab, Oropharyngeal Swab,
Nasal Swab and Other Specimen Types - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 56: France 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027

Table 57: France Current & Future Analysis for COVID-19 Testing
by End-Use - Hospitals, Diagnostic Centers and Other End-Uses -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 58: France 7-Year Perspective for COVID-19 Testing by
End-Use - Percentage Breakdown of Value Revenues for Hospitals,
Diagnostic Centers and Other End-Uses for the Years 2021 & 2027

GERMANY
Table 59: Germany Current & Future Analysis for COVID-19
Testing by Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 60: Germany 7-Year Perspective for COVID-19 Testing by
Product - Percentage Breakdown of Value Revenues for RT-PCR
Assay Kits and Immunoassay Test Strips/Cassettes for the Years
2021 & 2027

Table 61: Germany Current & Future Analysis for COVID-19
Testing by Specimen Type - Nasopharyngeal Swab, Oropharyngeal
Swab, Nasal Swab and Other Specimen Types - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 62: Germany 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027

Table 63: Germany Current & Future Analysis for COVID-19
Testing by End-Use - Hospitals, Diagnostic Centers and Other
End-Uses - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 64: Germany 7-Year Perspective for COVID-19 Testing by
End-Use - Percentage Breakdown of Value Revenues for Hospitals,
Diagnostic Centers and Other End-Uses for the Years 2021 & 2027

ITALY
Table 65: Italy Current & Future Analysis for COVID-19 Testing
by Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 66: Italy 7-Year Perspective for COVID-19 Testing by
Product - Percentage Breakdown of Value Revenues for RT-PCR
Assay Kits and Immunoassay Test Strips/Cassettes for the Years
2021 & 2027

Table 67: Italy Current & Future Analysis for COVID-19 Testing
by Specimen Type - Nasopharyngeal Swab, Oropharyngeal Swab,
Nasal Swab and Other Specimen Types - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 68: Italy 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027

Table 69: Italy Current & Future Analysis for COVID-19 Testing
by End-Use - Hospitals, Diagnostic Centers and Other End-Uses -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 70: Italy 7-Year Perspective for COVID-19 Testing by
End-Use - Percentage Breakdown of Value Revenues for Hospitals,
Diagnostic Centers and Other End-Uses for the Years 2021 & 2027

UNITED KINGDOM
Market Overview
Pandemic Exposes Deficiencies in the UK Healthcare System
UK Opens New Vaccine Centers to Expand Asymptomatic Covid-19
Testing
Mandatory COVID-19 Tests for UK-Bound Travellers
Mass Testing Program for COVID-19
Mass Testing in Schools
Mass Testing in Cities and Towns
New Mega Labs Speed Up COVID-19 Testing
Market Analytics
Table 71: UK Current & Future Analysis for COVID-19 Testing by
Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 72: UK 7-Year Perspective for COVID-19 Testing by Product -
Percentage Breakdown of Value Revenues for RT-PCR Assay Kits
and Immunoassay Test Strips/Cassettes for the Years 2021 & 2027

Table 73: UK Current & Future Analysis for COVID-19 Testing by
Specimen Type - Nasopharyngeal Swab, Oropharyngeal Swab, Nasal
Swab and Other Specimen Types - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 74: UK 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027

Table 75: UK Current & Future Analysis for COVID-19 Testing by
End-Use - Hospitals, Diagnostic Centers and Other End-Uses -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 76: UK 7-Year Perspective for COVID-19 Testing by End-Use -
Percentage Breakdown of Value Revenues for Hospitals,
Diagnostic Centers and Other End-Uses for the Years 2021 & 2027

SPAIN
Table 77: Spain Current & Future Analysis for COVID-19 Testing
by Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 78: Spain 7-Year Perspective for COVID-19 Testing by
Product - Percentage Breakdown of Value Revenues for RT-PCR
Assay Kits and Immunoassay Test Strips/Cassettes for the Years
2021 & 2027

Table 79: Spain Current & Future Analysis for COVID-19 Testing
by Specimen Type - Nasopharyngeal Swab, Oropharyngeal Swab,
Nasal Swab and Other Specimen Types - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 80: Spain 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027

Table 81: Spain Current & Future Analysis for COVID-19 Testing
by End-Use - Hospitals, Diagnostic Centers and Other End-Uses -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 82: Spain 7-Year Perspective for COVID-19 Testing by
End-Use - Percentage Breakdown of Value Revenues for Hospitals,
Diagnostic Centers and Other End-Uses for the Years 2021 & 2027

RUSSIA
Table 83: Russia Current & Future Analysis for COVID-19 Testing
by Product - RT-PCR Assay Kits and Immunoassay Test
Strips/Cassettes - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 84: Russia 7-Year Perspective for COVID-19 Testing by
Product - Percentage Breakdown of Value Revenues for RT-PCR
Assay Kits and Immunoassay Test Strips/Cassettes for the Years
2021 & 2027

Table 85: Russia Current & Future Analysis for COVID-19 Testing
by Specimen Type - Nasopharyngeal Swab, Oropharyngeal Swab,
Nasal Swab and Other Specimen Types - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 86: Russia 7-Year Perspective for COVID-19 Testing by
Specimen Type - Percentage Breakdown of Value Revenues for
Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab and Other
Specimen Types for the Years 2021 & 2027


Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06219575/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting